Satellos Bioscience (MSCL) investor relations material

Mission and scientific foundation

• Aims to restore natural muscle regeneration in Duchenne muscular dystrophy (DMD) and other muscle diseases, focusing on disease modification rather than stabilization.

• Founded in 2018, the company is in the clinical stage and is listed on TSX and NASDAQ.

• Scientific approach is based on Dr. Michael Rudnicki's discovery that DMD is primarily a disease of failed muscle regeneration.

• SAT-3247, an oral, once-daily tablet, is designed to be safe, tolerable, non-immunogenic, and suitable for all genetic mutations.

• SAT-3247 targets AAK1 to restore muscle stem cell polarity and enhance regeneration.

Market opportunity and unmet need

• DMD affects about 1 in 5,000 male births globally, with ~12,000 affected in the U.S.

• No approved therapies currently regenerate muscle; existing treatments have significant limitations and side effects.

• Peer companies in the DMD space have market capitalizations ranging from $0.2B to $5.0B.

Disease biology and mechanism of action

• Dystrophin is essential for both structural reinforcement and regulation of muscle stem cells.

• In DMD, muscle stem cells fail to produce enough progenitor cells, leading to progressive muscle loss.

• SAT-3247 inhibits AAK1, restoring the repair signal lost in the absence of dystrophin and enabling asymmetric stem cell division.